Radiotherapy of morphea-type basal cell carcinoma: Results in 127 cases

M. Caccialanza, R. Piccinno, E. Çuka, S. Alberti Violetti, M. Rozza

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background The morphea-type basal cell carcinoma (MBCC) is a rare form of basal cell carcinoma (BCC) with lower response to treatments than other types of BCC.

Objectives To evaluate the role of radiotherapy (RT) in the therapeutic strategy of MBCC.

Methods A retrospective study was performed on 127 patients affected with MBCC, who underwent RT in the period 1982-2013. RT was delivered with conventional energies ranging from 50 to 120 kV and the administration of a total dose ranging from 40 to 70 Gy (mean 56.17 Gy). The irradiated fields included a margin of 1.5 cm around the lesion.

Results The median follow-up time was 29 months (range 1-324 months). Complete remission was observed in 122 patients (96.06%), partial remission in one (0.78%). Three cases were non-responsive (2.36%). In one case (0.78%), the lesion failed to heal after RT, since the onset of radiodermatitis histologically ascertained. The cure rate was 81.08% after 5 years and 78.02% after 10 years from the end of RT. Twelve cases relapsed (10.2%). Conclusion Because of the frequent diagnostic delay and its ill-defined margins, MBCC is difficult to cure. Our results after 5 years from RT (cure rate 81.08%) are more satisfactory respect to the others reported in the literature (69% and 72.3%), but less good than those obtained in other forms of primary malignant neoplasms of the skin (92.43%). Nevertheless, we consider that RT plays an important role in the therapeutic strategy of MBCCs. In fact, it can be applied easily in elderly patients, and in peculiar localization of the disease (eyelid, nose and ear), without being invasive.

Original languageEnglish
Pages (from-to)1751-1755
Number of pages5
JournalJournal of the European Academy of Dermatology and Venereology
Volume28
Issue number12
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Localized Scleroderma
Basal Cell Carcinoma
Radiotherapy
Eyelid Diseases
Radiodermatitis
Nose Diseases
Ear Diseases
Skin Neoplasms
Therapeutics
Retrospective Studies

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases
  • Medicine(all)

Cite this

Radiotherapy of morphea-type basal cell carcinoma : Results in 127 cases. / Caccialanza, M.; Piccinno, R.; Çuka, E.; Alberti Violetti, S.; Rozza, M.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 28, No. 12, 01.12.2014, p. 1751-1755.

Research output: Contribution to journalArticle

@article{487f50fcfd304816b7ccd40cdaddf5dd,
title = "Radiotherapy of morphea-type basal cell carcinoma: Results in 127 cases",
abstract = "Background The morphea-type basal cell carcinoma (MBCC) is a rare form of basal cell carcinoma (BCC) with lower response to treatments than other types of BCC.Objectives To evaluate the role of radiotherapy (RT) in the therapeutic strategy of MBCC.Methods A retrospective study was performed on 127 patients affected with MBCC, who underwent RT in the period 1982-2013. RT was delivered with conventional energies ranging from 50 to 120 kV and the administration of a total dose ranging from 40 to 70 Gy (mean 56.17 Gy). The irradiated fields included a margin of 1.5 cm around the lesion.Results The median follow-up time was 29 months (range 1-324 months). Complete remission was observed in 122 patients (96.06{\%}), partial remission in one (0.78{\%}). Three cases were non-responsive (2.36{\%}). In one case (0.78{\%}), the lesion failed to heal after RT, since the onset of radiodermatitis histologically ascertained. The cure rate was 81.08{\%} after 5 years and 78.02{\%} after 10 years from the end of RT. Twelve cases relapsed (10.2{\%}). Conclusion Because of the frequent diagnostic delay and its ill-defined margins, MBCC is difficult to cure. Our results after 5 years from RT (cure rate 81.08{\%}) are more satisfactory respect to the others reported in the literature (69{\%} and 72.3{\%}), but less good than those obtained in other forms of primary malignant neoplasms of the skin (92.43{\%}). Nevertheless, we consider that RT plays an important role in the therapeutic strategy of MBCCs. In fact, it can be applied easily in elderly patients, and in peculiar localization of the disease (eyelid, nose and ear), without being invasive.",
author = "M. Caccialanza and R. Piccinno and E. {\cC}uka and {Alberti Violetti}, S. and M. Rozza",
year = "2014",
month = "12",
day = "1",
doi = "10.1111/jdv.12404",
language = "English",
volume = "28",
pages = "1751--1755",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "wiley",
number = "12",

}

TY - JOUR

T1 - Radiotherapy of morphea-type basal cell carcinoma

T2 - Results in 127 cases

AU - Caccialanza, M.

AU - Piccinno, R.

AU - Çuka, E.

AU - Alberti Violetti, S.

AU - Rozza, M.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Background The morphea-type basal cell carcinoma (MBCC) is a rare form of basal cell carcinoma (BCC) with lower response to treatments than other types of BCC.Objectives To evaluate the role of radiotherapy (RT) in the therapeutic strategy of MBCC.Methods A retrospective study was performed on 127 patients affected with MBCC, who underwent RT in the period 1982-2013. RT was delivered with conventional energies ranging from 50 to 120 kV and the administration of a total dose ranging from 40 to 70 Gy (mean 56.17 Gy). The irradiated fields included a margin of 1.5 cm around the lesion.Results The median follow-up time was 29 months (range 1-324 months). Complete remission was observed in 122 patients (96.06%), partial remission in one (0.78%). Three cases were non-responsive (2.36%). In one case (0.78%), the lesion failed to heal after RT, since the onset of radiodermatitis histologically ascertained. The cure rate was 81.08% after 5 years and 78.02% after 10 years from the end of RT. Twelve cases relapsed (10.2%). Conclusion Because of the frequent diagnostic delay and its ill-defined margins, MBCC is difficult to cure. Our results after 5 years from RT (cure rate 81.08%) are more satisfactory respect to the others reported in the literature (69% and 72.3%), but less good than those obtained in other forms of primary malignant neoplasms of the skin (92.43%). Nevertheless, we consider that RT plays an important role in the therapeutic strategy of MBCCs. In fact, it can be applied easily in elderly patients, and in peculiar localization of the disease (eyelid, nose and ear), without being invasive.

AB - Background The morphea-type basal cell carcinoma (MBCC) is a rare form of basal cell carcinoma (BCC) with lower response to treatments than other types of BCC.Objectives To evaluate the role of radiotherapy (RT) in the therapeutic strategy of MBCC.Methods A retrospective study was performed on 127 patients affected with MBCC, who underwent RT in the period 1982-2013. RT was delivered with conventional energies ranging from 50 to 120 kV and the administration of a total dose ranging from 40 to 70 Gy (mean 56.17 Gy). The irradiated fields included a margin of 1.5 cm around the lesion.Results The median follow-up time was 29 months (range 1-324 months). Complete remission was observed in 122 patients (96.06%), partial remission in one (0.78%). Three cases were non-responsive (2.36%). In one case (0.78%), the lesion failed to heal after RT, since the onset of radiodermatitis histologically ascertained. The cure rate was 81.08% after 5 years and 78.02% after 10 years from the end of RT. Twelve cases relapsed (10.2%). Conclusion Because of the frequent diagnostic delay and its ill-defined margins, MBCC is difficult to cure. Our results after 5 years from RT (cure rate 81.08%) are more satisfactory respect to the others reported in the literature (69% and 72.3%), but less good than those obtained in other forms of primary malignant neoplasms of the skin (92.43%). Nevertheless, we consider that RT plays an important role in the therapeutic strategy of MBCCs. In fact, it can be applied easily in elderly patients, and in peculiar localization of the disease (eyelid, nose and ear), without being invasive.

UR - http://www.scopus.com/inward/record.url?scp=84912038437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912038437&partnerID=8YFLogxK

U2 - 10.1111/jdv.12404

DO - 10.1111/jdv.12404

M3 - Article

C2 - 25564683

AN - SCOPUS:84912038437

VL - 28

SP - 1751

EP - 1755

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 12

ER -